Immunohistochemical and molecular cytogenetic evaluation of potential targets for tyrosine kinase inhibitors in Langerhans cell histiocytosis

Human Pathology

Volumn 43, Issue 12, 2012, Pages 2223-2228

  Caponetti, Gabriel C ^a   Miranda, Roberto N ^b   Althof, Pamela A ^c   Dobesh, Renae C ^c   Sanger, Warren G ^c   Medeiros, L Jeffrey ^b   Greiner, Timothy C ^a   Weisenburger, Dennis D ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Imatinib; Langerhans cell histiocytosis; Platelet derived growth factor receptor; Tyrosine kinase inhibitors

Indexed keywords

PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN S 100; PROTEIN TYROSINE KINASE INHIBITOR; T6 ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DERMATITIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; INFANT; LANGERHANS CELL HISTIOCYTOSIS; LYMPHADENITIS; MALE; ONCOGENE C KIT; PRESCHOOL CHILD; PROTEIN EXPRESSION; SCHOOL CHILD; TREATMENT RESPONSE;

ADOLESCENT; ADULT; ANTIGENS, CD1; CHILD; CHILD, PRESCHOOL; CYTOGENETICS; FEMALE; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; S100 PROTEINS;

EID: 84869491391     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2012.03.014     Document Type: Article

References (33)

1. C.L. Willman, L. Busque, and B.B. Griffith Langerhans'-cell histiocytosis (histiocytosis X) - a clonal proliferative disease N Engl J Med 331 1994 154 160
2. R.C. Yu, C. Chu, L. Buluwela, and A.C. Chu Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis Lancet 343 1994 767 768
3. S.A. Yousem, T.V. Colby, Y.Y. Chen, W.G. Chen, and L.M. Weiss Pulmonary Langerhans' cell histiocytosis: molecular analysis of clonality Am J Surg Pathol 25 2001 630 636
4. R. Jaffe, L.M. Weiss, and F. Facchetti Tumors derived from Langerhans cells S.H. Swerdlow, E. Campo, N.L. Harris, WHO classification of tumors of haematopoietic and lymphoid tissues 4th edn 2008 IARC Lyon, France 358 360
5. K. Chikwava, and R. Jaffe Langerin (CD207) staining in normal pediatric tissues, reactive lymph nodes, and childhood histiocytic disorders Pediatr Dev Pathol 7 2004 607 614
6. S.K. Lau, P.G. Chu, and L.M. Weiss Immunohistochemical expression of Langerin in Langerhans cell histiocytosis and non-Langerhans cell histiocytic disorders Am J Surg Pathol. 32 2008 615 619
7. T. Orii, H. Takeda, S. Kawata, K. Maeda, and M. Yamakawa Differential immunophenotypic analysis of dendritic cell tumours J Clin Pathol 63 2010 497 503
8. G.S. Pinkus, M.A. Lones, and F. Matsumura Langerhans cell histiocytosis immunohistochemical expression of fascin, a dendritic cell marker Am J Clin Pathol 118 2002 335 343
9. S.A. Pileri, T.M. Grogan, and N.L. Harris Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases Histopathology 41 2002 1 29
10. L. Krenacs, L. Tiszalvicz, and T. Krenacs Immunohistochemical detection of CD1a antigen in formalin-fixed and paraffin-embedded tissue sections with monoclonal antibody 010 J Pathol 171 1993 99 104
11. J.F. Emile, J. Wechsler, and N. Brousse Langerhans cell histiocytosis: definitive diagnosis with the use of monoclonal antibody 010 on routinely paraffin-embedded samples Am J Surg Pathol 19 1995 636 641
12. R.J. Arceci, M.K. Brenner, and J. Pritchard Controversies and new approaches to treatment of LCH Hematol Oncol Clin North Am 12 1998 339 357
13. O. Abla, R.M. Egeler, and S. Weitzman Langerhans cell histiocytosis: current concepts and treatments Cancer Treat Rev 36 2010 354 359
14. A. Arora, and E.M. Scholar Role of tyrosine kinase inhibitors in cancer therapy J Pharmacol Exp Ther. 315 2005 971 979
15. F. Grimminger, R.T. Schermuly, and H.A. Ghofrani Targeting non-malignant disorders with tyrosine kinase inhibitors Nat Rev Drug Discov. 9 2010 956 970
16. J.Y. Blay A decade of tyrosine kinase inhibitor therapy: historical and current perspectives on targeted therapy for GIST Cancer Treat Rev 37 2011 373 384
17. M. Bologna, C. Vicentini, P. Muzi, G. Pace, and A. Angelucci Cancer multitarget pharmacology in prostate tumors: tyrosine kinase inhibitors and beyond Curr Med Chem 18 2011 2827 2835
18. J. Gotlib Eosinophilic myeloid disorders: new classification and novel therapeutic strategies Curr Opin Hematol 17 2010 117 124
19. J. Cools, D.J. DeAngelo, and J. Gotlib A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome N Engl J Med 348 2003 1201 1214
20. A. Tefferi, J. Gotlib, and A. Pardanani Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update Mayo Clin Proc 85 2010 158 164
21. J.V. Jovanovic, J. Score, and K. Waghorn Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia Blood 109 2007 4635 4640
22. L. Montella, L. Insabato, and G. Palmieri Imatinib mesylate for cerebral Langerhans'-cell histiocytosis N Engl J Med 351 2004 1034 1035
23. G. Agreda-Vásquez, U. Popoca-Barriga, E. Oviedo, C. Lome-Maldonado, and S. Sánchez-Guerrero Gastrointestinal Langerhans cell histiocytosis responding to cladribine and imatinib mesylate Medicina Universitaria 12 2010 131 134
24. R.E. Brown Brief communication: morphoproteomic analysis of osteolytic Langerhans cell histiocytosis with therapeutic implications Ann Clin Lab Sci 35 2005 131 136
25. J. Haroche, Z. Amoura, and F. Charlotte Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis Blood 111 2008 5413 5415
26. R. Hoftberger, C. Haberler, and M. Wnorowski Immunohistochemical expression of imatinib targets in Langerhans cell histiocytosis (LCH): possible implications for treatment of LCH with imatinib [abstract] Acta Neuropathol 112 2006 355 387
27. J. Utikal, S. Ugurel, and H. Kurzen Imatinib as a treatment option for systemic non-Langerhans cell histiocytoses Arch Dermatol 143 2007 736 740
28. C. Wagner, H. Mohme, and T. Kromer-Olbrisch Langerhans cell histiocytosis: treatment failure with imatinib Arch Dermatol 145 2009 949 950
29. M. Nelson, S.L. Perkins, and B.J. Dave An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Oncology Group study CCG-5961 Br J Haematol 148 2010 600 610
30. C.H. Heldin, and B. Westermark The role of platelet-derived growth factor in vivo R.A.F. Clark, The molecular and cellular biology of wound repair 2nd ed 1996 Plenum Press New York 249 273
31. E.W. Raines, D.F. Bowen-Pope, and R. Ross Platelet-derived growth factor M.B. Sporn, A.B. Roberts, Handbook of experimental pharmacology: peptide growth factors and their receptors 1990 Springer-Verlag: Heidelberg Germany 173 262
32. R. Yao, and G.M. Cooper Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor Science 31 1995 2003 2006
33. M.Z. Hossain, A.B. Jagdale, P. Ao, A. Kazlauskas, and A.L. Boynton Disruption of gap junctional communication by the platelet-derived growth factor is mediated via multiple signaling pathways J Biol Chem 274 1999 10489 10496